Similar articles for PMID: 29550516

Year	Number of Results
1978	2
1979	2
1982	2
1988	2
1990	2
1991	2
1992	1
1993	2
1994	1
1996	2
1997	5
1998	5
1999	7
2000	3
2001	4
2002	5
2003	2
2004	4
2005	4
2006	6
2007	2
2008	3
2009	4
2010	3
2011	4
2012	5
2013	4
2014	2
2015	7
2016	9
2017	5
2018	4
2019	5
2020	4
2021	2
2022	3
2024	0

1

Improved immune response against HIV-1 Env antigen by enhancing EEV production via a K151E mutation in the A34R gene of replication-competent vaccinia virus Tiantan.

Yu J, Li Y, Zhong M, Yang J, Zhou D, Zhao B, Cao Y, Yan H, Zhang E, Yang Y, Feng Z, Qi X, Yan H. Yu J, et al. Antiviral Res. 2018 May;153:49-59. doi: 10.1016/j.antiviral.2018.03.004. Epub 2018 Mar 14. Antiviral Res. 2018. PMID: 29550516

2

HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection.

Liu Q, Li Y, Luo Z, Yang G, Liu Y, Liu Y, Sun M, Dai J, Li Q, Qin C, Shao Y. Liu Q, et al. AIDS. 2015 Mar 27;29(6):649-58. doi: 10.1097/QAD.0000000000000595. AIDS. 2015. PMID: 25849828

3

Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges.

Khattar SK, Manoharan V, Bhattarai B, LaBranche CC, Montefiori DC, Samal SK. Khattar SK, et al. mBio. 2015 Jul 21;6(4):e01005. doi: 10.1128/mBio.01005-15. mBio. 2015. PMID: 26199332 Free PMC article.

4

Vaccinia virus glycoprotein A34R is required for infectivity of extracellular enveloped virus.

McIntosh AA, Smith GL. McIntosh AA, et al. J Virol. 1996 Jan;70(1):272-81. doi: 10.1128/JVI.70.1.272-281.1996. J Virol. 1996. PMID: 8523536 Free PMC article.

5

HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.

García-Arriaza J, Perdiguero B, Heeney JL, Seaman MS, Montefiori DC, Yates NL, Tomaras GD, Ferrari G, Foulds KE, Roederer M, Self SG, Borate B, Gottardo R, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo AD, Weiss DE, Lee C, Kibler KV, Jacobs BL, Wagner R, Ding S, Pantaleo G, Esteban M. García-Arriaza J, et al. J Virol. 2017 Apr 13;91(9):e02182-16. doi: 10.1128/JVI.02182-16. Print 2017 May 1. J Virol. 2017. PMID: 28179536 Free PMC article.

6

UV-inactivated vaccinia virus (VV) in a multi-envelope DNA-VV-protein (DVP) HIV-1 vaccine protects macaques from lethal challenge with heterologous SHIV.

Jones BG, Sealy RE, Zhan X, Freiden PJ, Surman SL, Blanchard JL, Hurwitz JL. Jones BG, et al. Vaccine. 2012 May 2;30(21):3188-95. doi: 10.1016/j.vaccine.2012.03.001. Epub 2012 Mar 14. Vaccine. 2012. PMID: 22425790 Free PMC article.

7

Env-2dCD4 S60C complexes act as super immunogens and elicit potent, broadly neutralizing antibodies against clinically relevant human immunodeficiency virus type 1 (HIV-1).

Killick MA, Grant ML, Cerutti NM, Capovilla A, Papathanasopoulos MA. Killick MA, et al. Vaccine. 2015 Nov 17;33(46):6298-306. doi: 10.1016/j.vaccine.2015.09.056. Epub 2015 Oct 1. Vaccine. 2015. PMID: 26432912

8

Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.

Gherardi MM, Nájera JL, Pérez-Jiménez E, Guerra S, García-Sastre A, Esteban M. Gherardi MM, et al. J Virol. 2003 Jun;77(12):7048-57. doi: 10.1128/jvi.77.12.7048-7057.2003. J Virol. 2003. PMID: 12768024 Free PMC article.

9

Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.

Andersson AC, Ragonnaud E, Seaton KE, Sawant S, Folgori A, Colloca S, Labranche C, Montefiori DC, Tomaras GD, Holst PJ. Andersson AC, et al. Vaccine. 2016 Oct 17;34(44):5344-5351. doi: 10.1016/j.vaccine.2016.08.089. Epub 2016 Sep 12. Vaccine. 2016. PMID: 27633665 Free PMC article.

10

A human immunodeficiency virus type 1 Env-granulocyte-macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine.

Rodr Guez D, Rodr Guez JR, Llorente M, V Zquez I, Lucas P, Esteban M, Mart Nez-A C, Del Real G. Rodr Guez D, et al. J Gen Virol. 1999 Jan;80 ( Pt 1):217-223. doi: 10.1099/0022-1317-80-1-217. J Gen Virol. 1999. PMID: 9934705

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

122 results

Results by year